TABLE 3.
Commercial blockers from Boehringer (Mannheim, Germany) for elimination of nonspecific reactions
| Blocker (catalog no.) | Recommended working concn (trial concn) | Possible mechanism of elimination of nonspecificity | Blocking effect |
|---|---|---|---|
| MAK 33 (1200 941) | 50–1,000 μg/ml (1,000 μg/ml) | Monoclonal antibody against Fc IgG1 for elimination of anti-mouse antibodies | None |
| Poly MAK 33 (1368 338) | 0.5–50 μg/ml (50 μg/ml) | Polymeric monoclonal antibody against Fc and Fab IgG1 for elimination of anti-mouse antibodies | None |
| Poly MAK 2b/2a (368 338) | 0.5–50 μg/ml (50 μg/ml) | Polymeric monoclonal antibody against Fc and Fab IgG2 for elimination of anti-mouse antibodies | None |
| H-IgG/Fab-Poly (BMO 9000 041) | 0.5–500 μg/ml (500 μg/ml) | Polymeric polyclonal human IgG for elimination of anti-human IgG-directed interferences | None |
| B-IgG (1293 621) | 0.5–2.5 mg/ml (2.5 mg/ml) | Bovine IgG | None |
| Poly BSA I (1 539 302) | 0.1–50 mg/ml (5 mg/ml) | Elimination of endogenous nonspecified interferences | None |
| Poly BSA II (1 816 438) | 0.1–50 mg/ml (5 mg/ml) | Elimination of endogenous nonspecified interferences | None |
| Poly BPLA I (BMO 9000 045) | 0.1–50 mg/ml (10 mg/ml) | Bovine plasma albumin II for elimination of endogenous nonspecified interferences | None |
| Poly BPLA IV (BMO 9000 044) | 0.1–50 mg/ml (10 mg/ml) | Bovine plasma albumin II for elimination of endogenous nonspecified interferences | None |
| Poly Pod, inactivated (BMO 9000 026) | 0.5–100 μg/ml (tested up to a concn of 1 mg/ml) | Polymerized horseradish peroxidase | Reduction of nonspecificity at 0.5–1 mg/ml; however, no complete abolishment in some samples |